SCHEMBL4434712

SCHEMBL4434712

NC(=O)OS(=O)(=O)N1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
POLB P06746 1/20 0.41
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
USP2 O75604 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601476 0.98 CA1 (0.42) CA1CA2POLBALDH1A1KMT2A
SCHEMBL4432705 0.79 CA12 (0.46) POLBTSHRMAPK1L3MBTL1SMN1; SMN2
SCHEMBL4532361 0.79 HTT (0.35) ALDH1A1HPGDL3MBTL1SMN1; SMN2
SCHEMBL4003537 0.78 CA1 (0.41) CA1CA2POLBALDH1A1KMT2A
SCHEMBL27924346 0.74 CA1 (0.37) CA1CA2POLBALDH1A1KMT2A
SCHEMBL28238995 0.74 HSD11B1 (0.40) POLBALDH1A1KMT2AMEN1MAPT
SCHEMBL28578134 0.72 ALDH1A1 (0.33) POLBALDH1A1KMT2AGAASMN1; SMN2
SCHEMBL28504878 0.72 NAMPT (0.31) POLBALDH1A1
SCHEMBL20599612 0.72 ALDH1A1 (0.42) CA1CA2POLBALDH1A1KMT2A
SCHEMBL27550826 0.72 CA1 (0.55) CA1CA2POLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1404829-A Double inhibitor synthesized by wax ester and cholesterol ester for inbibiting generation of sebum WARNER LAMBERT CO (US) 2003-03-26 CN claimed
CN-1370526-A Treating method of nuclear factor-KB mediated diseases and dysfuction WANER LONGBER CO (US) 2002-09-25 CN claimed
CN-113316566-A Compounds and compositions for treating conditions associated with NLRP activity 诺华股份有限公司 2021-08-27 CN disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
CN-1404829-A Double inhibitor synthesized by wax ester and cholesterol ester for inbibiting generation of sebum WARNER LAMBERT CO (US) 2003-03-26 CN disclosed
CN-1370526-A Treating method of nuclear factor-KB mediated diseases and dysfuction WANER LONGBER CO (US) 2002-09-25 CN disclosed